




PHARMACEUTICAL 2021

Paratek Pharmaceuticals Inc.
Rank 339 of 402





RealRate

PHARMACEUTICAL 2021

Paratek Pharmaceuticals Inc.
Rank 339 of 402



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 228% points.

The company's Economic Capital Ratio, given in the ranking table, is -120%, being 167% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	164,117
Cost of Goods Sold	8,651
Intangible Assets	829
Liabilities, Current	23,953
Liabilities, Non-Current	255,160
Other Assets	10,943
Other Compr. Net Income	-70
Other Expenses	20,240
Other Liabilities	0
Other Net Income	-797
Other Revenues	46,924
Property and Equipment	964
Research and Development	23,922
Selling, General and Administrative Expense	89,855

Output Variable	Value in 1000 USD
Assets	176,853
Liabilities	279,113
Expenses	142,668
Revenues	46,924
Stockholders Equity	-102,260
Net Income	-96,541
Comprehensive Net Income	-96,576
Economic Capital Ratio	-120%